Loading

brain

  • by Paul Armentano, NORML Deputy Director November 12, 2014

    NORML’s Deputy Director today on Alternet.org addressed new media claims that cannabis use can potentially shrink the brain:

    [excerpt] A new study identifying minor differences in the brain imaging of habitual marijuana consumers compared to non-users may be ideal for stimulating sensational headlines (e.g., “Regular pot smokers have shrunken brains, study says,” Los Angeles Times, November 10), but tells us little in regard to whether pot poses actual health risks.

    Specifically, an MRI scan revealed less gray matter in the orbital frontal cortex of pot-smoking subjects compared to those who had never used the drug. Researchers also identified increased connectivity between certain regions of the brain in regular marijuana users compared with non-users.

    So precisely what do these findings tell us in regard to pot use and health? Not much. Since the study design is not longitudinal, investigators cannot determine whether these differences are caused by subject’s cannabis use, whether these differences existed prior to subjects’ ever trying cannabis, or whether these differences persist when users’ cannabis consumption ceases.

    Most importantly, investigators in this study failed to determine whether any of these differences are positively associated with any measurable adverse performance outcomes, such as cognitive performance or quality of life. It may be that these cannabis users are functioning in their daily lives in a manner that is indistinguishable from controls, in which case the imaging differences may hold little if any real-world significance. (In fact, one of the paper’s authors acknowledged, “[C]hronic users appear to be doing fine.”)

    Full text of NORML’s response, “Media Leaping to Extremely Faulty Conclusions from Study on the Effects of Marijuana on the Brain,” appears online here.

  • by Paul Armentano, NORML Deputy Director October 22, 2014

    Moderate cannabis consumption by young people is not positively associated with changes in intelligence quotient (IQ), according to data presented this week at the European College of Neuropsychopharmacology annual congress in Berlin, Germany.

    Investigators at the University College of London analyzed data from 2,612 subjects who had their IQ tested at the age of eight and again at age 15. They reported no relationship between cannabis use and lower IQ at age 15 when confounding factors such as subjects’ history of alcohol use and cigarette use were taken into account.

    “In particular alcohol use was found to be strongly associated with IQ decline,” the authors wrote in a press release cited by The Washington Post. “No other factors were found to be predictive of IQ change.”

    Quoted in the Independent Business Times, the study’s lead author said: “Our findings suggest cannabis may not have a detrimental effect on cognition, once we account for other related factors particularly cigarette and alcohol use. This may suggest that previous research findings showing poorer cognitive performance in cannabis users may have resulted from the lifestyle, behavior and personal history typically associated with cannabis use, rather than cannabis use itself.”

    The investigators acknowledged that more chronic marijuana use, defined in the study as a subject’s admission of having consumed cannabis 50 times or more by age 15, was correlated with slightly poorer exam results at the age of 16 — even after controlling for other variables. However, investigators admitted: “It’s hard to know what causes what. Do kids do badly at school because they are smoking weed, or do they smoke weed because they’re doing badly?”

    Commenting on the newly presented data, the meeting’s Chair, Guy Goodwin, from the University of Oxford, told BBC News: “This is a potentially important study because it suggests that the current focus on the alleged harms of cannabis may be obscuring the fact that its use is often correlated with that of other even more freely available drugs and possibly lifestyle factors.”

    In a recent review published in the New England Journal of Medicine, the NIDA Director Nora Volkow alleged that cannabis use, particularly by adolescents, is associated with brain alterations and lower IQ. However, the IQ study cited by Ms. Volkow as the basis of her claim was later questioned in a separate analysis published in the Proceedings of the National Academy of Sciences. That paper suggested that socioeconomics, not subjects’ cannabis use, was responsible for differences in IQ and that the plant’s “true effect [on intelligence quotient] could be zero.”

    A previous assessment of cannabis use and its potential impact on intelligence quotient in a cohort of young people tracked since birth reported, “[M]arijuana does not have a long-term negative impact on global intelligence.”

  • by Paul Armentano, NORML Deputy Director April 18, 2014

    The mainstream media launched into a reefer mad frenzy this week after researchers from Harvard University in Boston and Northwestern University in Chicago published the results of a neuroimaging study assessing the brains of a small cohort of regular marijuana smokers and non-users. The brain scans identified various differences between the two groups in three aspects of brain morphometry: gray matter density, volume, and shape. These differences triggered dozens of high-profile media outlets to lose their collective minds. Here’s a sampling:

    CNN: Casual marijuana use may damage your brain

    Financial Post: Study proves occasional marijuana use is mind altering

    Time: Recreational pot use harmful to young people’s brains

    International Business Times: Casual Marijuana Smoking at Young Age May Cause Irreparable Brain Damage – Even at One Joint Per Week

    UK Telegraph: Smoking cannabis will change you. That’s not a ‘risk’, it’s a certainty

    Yet despite the sensationalist headlines, the study itself was hardly newsworthy. Decades of research pertaining to the potential residual adverse effects of cannabis on brain cognition have failed to support the notion that marijuana poses any sort of permanent brain deficits. And as I write today on Alternet.org, this study similarly failed to report any sort of real-world adverse consequences associated with cannabis use:

    Why the Media’s Fear-Mongering on Marijuana Effects on the Brain Is Faulty
    via Alternet.org

    [excerpt] Using high–resolution MRI imaging, scientists identified specific changes in particular regions of the brain that they inferred were likely due to marijuana exposure. (Since researchers only performed a single MRI session, they could not say definitively whether these changes were, in fact, caused by cannabis or whether they existed prior to subjects’ use of the plant.) Notably, however, these changes did not appear to be associated with any overt adverse effects in subjects’ actual cognition or behavior. (Separate studies assessing youth use of legal intoxicants, such as nicotine and alcohol, have also been associated with documented changes in brain structure. Ditto for caffeine intake in preclinical models. These findings have received far less media attention.)

    Both the cases (20 marijuana users) and controls (20 nonusers) in the study were recruited from local universities, undermining the notion that the alleged ‘brain damaged potheads’ were any more academically challenged than their non-using peers. Further, as summarized by HealthDay: “Psychiatric interviews revealed that the pot smokers did not meet criteria for drug dependence. For example, marijuana use did not interfere with their studies, work or other activities, and they had not needed to increase the amount they used to get the same high.”

    In other words, case subjects and controls appeared to function similarly in their professional and academic endeavors.

    You can read the full text of my response here.

    [Update: I have a separate op/ed (“Smoke weed, turn into a pothead? Not so fast”) responding to this paper online in The Los Angeles Times here.]

    Fortunately, my critique of this latest paper — and in particular the mainstream media’s sensationalist and erroneous coverage of its findings — is far from the only one. Below are links to several other excellent analyses:

    MedPage Today: Striking a Nerve: Bungling the Cannabis Story

    Daily Beast: No, Weed Won’t Rot Your Brain

    Bits of DNA (blog): Does researching casual marijuana use cause brain abnormalities?

    DPA Blog: Does Smoking Dope Really Make You a Dope?

  • by Paul Armentano, NORML Deputy Director June 6, 2013

    Recent preclinical studies published over the past several weeks provide further evidence that cannabinoids are both neuroprotective and cardioprotective.

    A May 30th blog post on the website Science20.com sums up new findings from Israel regarding the ability of low doses of THC to prevent brain damage in animals.

    Prof. Yosef Sarne in the Department of Physiology and Pharmacology at Tel Aviv University says that [cannabis] … has neuroprotective qualities. He has found that extremely low doses of THC — the psychoactive component of marijuana — protects the brain from long-term cognitive damage in the wake of injury from hypoxia (lack of oxygen), seizures, or toxic drugs.

    Previous studies focused on injecting high doses of THC within a very short time frame – approximately 30 minutes – before or after injury. Sarne’s papers in Behavioural Brain Research and Experimental Brain Research say that even extremely low doses of THC – around 1,000 to 10,000 times less than that in a conventional marijuana cigarette – administered over a wide window of 1 to 7 days before or 1 to 3 days after injury can jump-start biochemical processes which protect brain cells and preserve cognitive function over time.

    … In the lab, the researchers injected mice with a single low dose of THC either before or after exposing them to brain trauma. A control group of mice sustained brain injury but did not receive the THC treatment. When the mice were examined 3 to 7 weeks after initial injury, recipients of the THC treatment performed better in behavioral tests measuring learning and memory. Additionally, biochemical studies showed heightened amounts of neuroprotective chemicals in the treatment group compared to the control group.

    … This treatment, especially in light of the long time frame for administration and the low dosage, could be applicable to many cases of brain injury and be safer over time, Sarne says.

    NORML has previously reported on separate preclinical data documenting that cannabinoids can promote neurogenesis (the active production of new neurons) in laboratory animals as well observational data indicating that marijuana may provide neuroprotection against alcohol-induced impairment in adolescent subjects.

    In addition, recently published preclinical studies also indicate that cannabinoids may offer benefits to the heart. Animal data published in the June issue of the scientific journal Biochemical Pharmacology reports that THC administration “is a safe and effective treatment that reduces myocardial ischemic (heart attack) damage.” Authors concluded: “[O]ur study provides novel evidence for the beneficial use of extremely low doses of THC, doses that do not elicit any psychoactive side effects, in order to protect the heart from ischemic insults. THC can be used as a pre-conditioning drug in cases in which ischemic insult to the heart is anticipated, such as during cardiac surgery or percutaneous coronary intervention. If post-conditioning with THC will be found effective, it could also be used following myocardial infarction.”

    The results of a separate preclinical trial, published in May in the journal Environmental Toxicology and Pharmacology, report that the administration of the non-psychotropic cannabinoid cannabidiol (CBD) is protective against cardiotoxicity in rats. “[C]annabidiol ameliorated doxorubicin-induced cardiac injury,” the study concluded. “These results indicate that cannabidiol represents a potential protective agent.”

    In February of this year, investigators at the Bar-Ilan University in Israel also reported that the administration of delta-9-THC protects heart muscle cells from injury during hypoxia (a deficiency in the levels of oxygen in the blood). THC “delaying the onset of irreversible cell injury … on hypoxia-exposed cardiac cells in culture,” authors found. They concluded, “This research demonstrates that THC has beneficial effects on cardiac cells and supports the consideration of marijuana for specific medical uses.”

  • by Paul Armentano, NORML Deputy Director July 27, 2011

    [Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To have NORML’s media alerts and legislative advisories delivered straight to your in-box, sign up here.]

    The consumption of cannabis, even long-term, poses few adverse effects on cognitive performance, according to clinical trial data to be published in the scientific journal Addiction.

    Investigators at the University of Melbourne and the Australian National University, Center for Mental Health Research assessed the impact of cannabis use on various measures of memory and intelligence in over 2,000 self-identified marijuana consumers and non-users over an eight-year period. Among cannabis consumers, subjects were grouped into the following categories: ‘heavy’ (once a week or more) users, ‘light’ users, ‘former heavy’ users, ‘former light’ users, and ‘always former’ — a category that consisted of respondents who had ceased using marijuana prior to their entry into the study.

    Researchers reported: “Only with respect to the immediate recall measure was there evidence of an improved performance associated with sustained abstinence from cannabis, with outcomes similar to those who had never used cannabis at the end point. On the remaining cognitive measures, after controlling for education and other characteristics, there were no significant differences associated with cannabis consumption.”

    They concluded, “Therefore, the adverse impacts of cannabis use on cognitive functions either appear to be related to pre-existing factors or are reversible in this community cohort even after potentially extended periods of use.”

    Separate studies have previously reported that long-term marijuana use is not associated with residual deficits in neurocognitive function. Specifically, a 2001 study published in the journal Archives of General Psychiatry found that chronic cannabis consumers who abstained from the drug for one week “showed virtually no significant differences from control subjects (those who had smoked marijuana less than 50 times in their lives) on a battery of 10 neuropsychological tests. … Former heavy users, who had consumed little or no cannabis in the three months before testing, [also] showed no significant differences from control subjects on any of these tests on any of the testing days.”

    Additionally, studies have also implied that cannabis may be neuroprotective against alcohol-induced cognitive deficits. A 2009 study by investigators at the University of California and San Diego reported that binge drinkers who also used cannabis experienced significantly less white matter damage to the brain as compared to subjects who consumed alcohol alone.

    For more information regarding the impact of cannabis on brain function, see NORML’s factsheet ‘Cannabis and the Brain: A User’s Guide,’ here.

Page 1 of 212